EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial

David R Boulware iD, Mucunguzi Atukunda, Enock Kagimu, Abdu K Musubire, Andrew Akampurira, Lillian Tugume, Kenneth Ssebambulidde, John Kasibante, Laura Nsangi, Timothy Mugabi, Jane Gakuru, Sarah Kimuda und 17 weitere

Clinical Infectious Diseases · 15.12.2023 · 77 (12) · 1659-1667

DOI: 10.1093/cid/ciad440 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.08.2023. Verfasst von David R Boulware und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Vaccines. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed.

Methods

In our randomized clinical trial, we tested oral lipid nanocrystal (LNC) amphotericin B (MAT2203, Matinas Biopharma) vs intravenous (IV) amphotericin for human immunodeficiency virus–associated cryptococcal meningitis in 4 sequential cohorts. Two pilot cohorts assessed safety and tolerability (n = 10 each), and 2 cohorts assessed efficacy with/without 2 IV loading doses (n = 40 each). The experimental arm received 1.8 g/d oral LNC amphotericin through 2 weeks with 100 mg/kg/d flucytosine, then 1.2 g/d LNC amphotericin through 6 weeks. The randomized control arm (n = 41) received 7 days of IV amphotericin with flucytosine, then 7 days of fluconazole 1200 mg/d. The primary end point was cerebrospinal fluid (CSF) early fungicidal activity (EFA).

Results

We randomized 80 participants to oral LNC amphotericin + flucytosine with (n = 40) and without (n = 40) 2 IV loading doses and 41 control participants to IV amphotericin + flucytosine. Mean EFA was 0.40 log10 colony-forming units (CFU)/mL/d for all-oral LNC amphotericin, 0.42 log10 Cryptococcus CFU/mL/d for oral LNC amphotericin with IV loading doses, and 0.46 log10 CFU/mL/d for IV amphotericin controls. LNC amphotericin groups achieved 2-week CSF sterility in 63% (44 of 70) vs 68% (23 of 34) of controls. The 18-week survival was 85% (34 of 40) with all-oral LNC amphotericin, 90% (36 of 40) with oral LNC amphotericin given IV loading doses, and 85% (35 of 41) with IV amphotericin. Grade 3–4 laboratory adverse events occurred less frequently in LNC amphotericin groups (41%) than the IV amphotericin group (61%, P = .05), particularly for anemia (21% vs 44%; P = .01) and potassium (5% vs 17%; P = .04).

Conclusions

This new oral amphotericin B LNC formulation appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than IV amphotericin. Clinical Trials Registration NCT04031833.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningitis, CryptococcalVaccinesHumansAmphotericin BFlucytosineDrug Therapy, CombinationAntifungal AgentsFluconazoleLipids

Stichwörter der Autor:innen

AIDS-related opportunistic infectionHIVamphotericin Bcryptococcal meningitisrandomized controlled trial

Substanzen

Amphotericin BFlucytosineAntifungal AgentsFluconazoleVaccinesLipids

Autor:innen und Institutionen

  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Infectious Diseases Institute, Makerere University, Kampala, Uganda.
  • Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda.
  • Matinas Biopharma Nanotechnologies, Bedminster, New Jersey, USA.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: David R Boulware

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • Intramural NIH HHS
  • FIC NIH HHS
  • NIH HHS
  • NIAID NIH HHS
  • NIH
  • Matinas BioPharma

Zitieren

APA

Boulware, D. R., Atukunda, M., Kagimu, E., Musubire, A. K., Akampurira, A., Tugume, L., Ssebambulidde, K., Kasibante, J., Nsangi, L., Mugabi, T., Gakuru, J., Kimuda, S., Kasozi, D., Namombwe, S., Turyasingura, I., Rutakingirwa, M. K., Mpoza, E., Kigozi, E., Muzoora, C., …, & Meya, D. B. (2023). Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial. Clinical Infectious Diseases, 77(12), 1659-1667. https://doi.org/10.1093/cid/ciad440

Vancouver

Boulware DR, Atukunda M, Kagimu E, Musubire AK, Akampurira A, Tugume L, et al. Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial. Clinical Infectious Diseases. 2023;77(12):1659-1667. doi:10.1093/cid/ciad440

BibTeX
@article{Boulware2023,
  author = {Boulware, David R and Atukunda, Mucunguzi and Kagimu, Enock and Musubire, Abdu K and Akampurira, Andrew and Tugume, Lillian and Ssebambulidde, Kenneth and Kasibante, John and Nsangi, Laura and Mugabi, Timothy and Gakuru, Jane and Kimuda, Sarah and Kasozi, Derrick and Namombwe, Suzan and Turyasingura, Isaac and Rutakingirwa, Morris K and Mpoza, Edward and Kigozi, Enos and Muzoora, Conrad and Ellis, Jayne and Skipper, Caleb P and Matkovits, Theresa and Williamson, Peter R and Williams, Darlisha A and Fieberg, Ann and Hullsiek, Kathy H and Abassi, Mahsa and Dai, Biyue and Meya, David B},
  title = {Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {12},
  pages = {1659--1667},
  doi = {10.1093/cid/ciad440}
}
Kostenlos starten →